Proteomics Study of the Synergistic Killing of Tigecycline in Combination With Aminoglycosides Against Carbapenem-Resistant Klebsiella pneumoniae. 2022

Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
Department of Pulmonary and Critical Care Medicine, Peking University People's Hospital, Beijing, China.

Co-administration of antibiotics with synergistic effects is one method to combat carbapenem-resistant organisms. Although the synergistic effects of tigecycline combined with aminoglycosides against carbapenem-resistant Klebsiella pneumoniae (CRKP) have been demonstrated in vitro and in animal models, the underlying mechanism remains elusive. Here we used proteomics analysis to assess the short-term bacterial responses to tigecycline and aminoglycosides alone or in combination. Emergence of tigecycline resistance during treatment and the susceptibility of tigecycline-resistant strains to aminoglycosides was further evaluated. The proteomic responses to tigecycline and aminoglycosides were divergent in monotherapy, with proteomic alterations to combination therapy dominated by tigecycline. Adaptive responses to tigecycline were associated with the upregulation of oxidative phosphorylation and translation-related proteins. These responses might confer CRKP hypersensitivity towards aminoglycosides by increasing the drug uptake and binding targets. Meanwhile, tigecycline might perturb adaptive responses to aminoglycosides through inhibition of heat shock response. Tigecycline-resistant strains could be isolated within 24 h exposure even in strains without heteroresistance, and the sensitivity to aminoglycosides significantly increased in resistant strains. Overall, these findings demonstrated that adaption to tigecycline in CRKP was a double-edged sword associated with the synergistic killing in tigecycline-aminoglycoside combination. Evolutionary hypersensitivity can provide novel insight into the mechanisms of antibiotic synergistic effects.

UI MeSH Term Description Entries
D007710 Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA. Infections, Klebsiella,Infection, Klebsiella,Klebsiella Infection
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000073182 Carbapenem-Resistant Enterobacteriaceae Strains of Enterobacteriaceae that are resistant to CARBAPENEMS, primarily due to the acquisition of carbapenemase (BETA-LACTAMASE) genes. Carbapenemase-Producing Enterobacteriaceae
D000078304 Tigecycline A tetracycline derivative that acts as a protein synthesis inhibitor. It is used as an antibacterial agent for the systemic treatment of complicated skin and intra-abdominal infections. It is also used for the treatment of community-acquired pneumonia. 9-(tert-Butylglycylamido)minocycline,GAR 936,GAR-936,TBG-MINO,Tygacil,GAR936
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015780 Carbapenems A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain. Antibiotics, Carbapenem,Carbapenem,Carbapenem Antibiotics
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
June 2021, Antibiotics (Basel, Switzerland),
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
July 2021, The Journal of antimicrobial chemotherapy,
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
May 2022, Antibiotics (Basel, Switzerland),
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
November 2019, Annals of palliative medicine,
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
May 2024, Journal of infection and public health,
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
January 2021, Frontiers in microbiology,
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
March 2019, Antimicrobial agents and chemotherapy,
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
December 2020, Microorganisms,
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
November 2021, Pathogens (Basel, Switzerland),
Xinqian Ma, and Shining Fu, and Yifan Wang, and Lili Zhao, and Wenyi Yu, and Yukun He, and Wentao Ni, and Zhancheng Gao
September 2015, Journal of global antimicrobial resistance,
Copied contents to your clipboard!